Accession NumberDB00879  (APRD00226)
TypeSmall Molecule
GroupsApproved, Investigational

Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) for the treatment of HIV infection in adults. Emtricitabine is an analogue of cytidine. The drug works by inhibiting reverse transcriptase, the enzyme that copies HIV RNA into new viral DNA.

External IDs 524W91 / BW-524W91
Product Ingredients Not Available
Product Images
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
EmtrivaCapsule200 mg/1OralExcella Gmb H2003-07-02Not applicableUs
EmtrivaCapsule200 mg/1OralRemedy Repack2008-05-172017-05-02Us
EmtrivaCapsule200 mgOralGilead Sciences2006-03-03Not applicableCanada
EmtrivaCapsule200 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
EmtrivaCapsule200 mg/1OralGilead Sciences2003-07-02Not applicableUs
EmtrivaCapsule200 mg/1OralPhysicians Total Care, Inc.2003-07-10Not applicableUs
EmtrivaSolution10 mg/mLOralGilead Sciences2005-09-28Not applicableUs
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
CoviracilNot Available
Brand mixtures
Apo-emtricitabine-tenofovirApotex Corporation
AtriplaLake Erie Medical Dba Quality Care Produts Llc
CompleraPhysicians Total Care, Inc.
DescovyGilead Sciences
GenvoyaGilead Sciences
OdefseyA S Medication Solutions
StribildState of Florida DOH Central Pharmacy
TruvadaH.J. Harkins Company
CAS number143491-57-0
WeightAverage: 247.247
Monoisotopic: 247.042690096
Chemical FormulaC8H10FN3O3S
NC1=NC(=O)N(C=C1F)[C@@H]1CS[[email protected]](CO)O1

Indicated, in combination with other antiretroviral agents, for the treatment of HIV-1 infection in adults and for postexposure prophylaxis of HIV infection in health care workers and others exposed occupationally or nonoccupationally via percutaneous injury or mucous membrane or nonintact skin contact with blood, tissues, or other body fluids associated with risk for transmission of the virus.

Structured Indications

Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) with activity against Human Immunodeficiency Virus Type 1 (HIV-1). Emtricitabine helps to block HIV reverse transcriptase, a chemical in your body (enzyme) that is needed for HIV to multiply. Emtricitabine is always used with other anti-HIV medicines to treat people with HIV infection. Emtricitabine may lower the amount of HIV in the blood (viral load). Emtricitabine may also help to increase the number of T cells called CD4 cells. Lowering the amount of HIV in the blood lowers the chance of death or infections that happen when your immune system is weak (opportunistic infections). People taking emtricitabine may still get opportunistic infections or other conditions that happen with HIV infection.

Mechanism of action

Emtricitabine works by inhibiting reverse transcriptase, the enzyme that copies HIV RNA into new viral DNA. Emtricitabine is a synthetic nucleoside analogue of cytidine. It is phosphorylated by cellular enzymes to form emtricitabine 5'-triphosphate, which is responsible for the inhibition of HIV-1 reverse transcriptase. It competes with the natural substrate deoxycytidine 5'-triphosphate and incorporates into nascent viral DNA, resulting in early chain termination. Therefore emtricitabine inhibits the activity of HIV-1 reverse transcriptase (RT) both by competing with the natural substrate deoxycytidine 5'-triphosphate and by its incorporation into viral DNA. By inhibiting HIV-1 reverse transcriptase, emtricitabine can help to lower the amount of HIV, or "viral load", in a patient's body and can indirectly increase the number of immune system cells (called T cells or CD4+ T-cells). Both of these changes are associated with healthier immune systems and decreased likelihood of serious illness.

TargetKindPharmacological actionActionsOrganismUniProt ID
Reverse transcriptase/RNaseHProteinyes
Human immunodeficiency virus 1Q72547 details
Related Articles

Rapidly absorbed (mean absolute bioavailability of 93% for capsules, and 75% for solution). Food does not effect absorption.

Volume of distributionNot Available
Protein binding

Very low (less than 4%)


Minimally transformed (13%), most appears unchanged in urine (86%). The biotransformation of emtricitabine includes oxidation of the thiol moiety to form the 3′-sulfoxide diastereomers (~ 9% of dose) and conjugation with glucuronic acid to form 2′-O-glucuronide (~ 4% of dose). In vitro studies indicate emtricitabine is not an inhibitor or cytochrome P450 enzymes.

Route of elimination

The renal clearance of emtricitabine is greater than the estimated creatinine clearance, suggesting elimination by both glomerular filtration and active tubular secretion.

Half life

10 hours

  • 302 +/- 94 mL/min [Renal Function Creatinine Clearance>80 ml/min]
  • 168 +/- 10 mL/min [Renal Function Creatinine Clearance 50-80 ml/min]
  • 138 +/- 28 mL/min [Renal Function Creatinine Clearance 30-49 ml/min]
  • 99 +/- 6 mL/min [Renal Function Creatinine Clearance<30 ml/min]
  • 64 +/- 12 mL/min [ESRD patients requiring dialysis]

Symptoms of overdose include serious liver problems (hepatotoxicity, with liver enlargement and fat in the liver called steatosis) or a lactic acidosis (buildup of an acid in the blood).

Affected organisms
  • Human Immunodeficiency Virus
PathwayCategorySMPDB ID
Emtricitabine Action PathwayDrug actionSMP00741
Pharmacogenomic Effects/ADRs Not Available
Drug Interactions
DrugInteractionDrug group
GanciclovirThe risk or severity of adverse effects can be increased when Ganciclovir is combined with Emtricitabine.Approved, Investigational
LamivudineThe risk or severity of adverse effects can be increased when Lamivudine is combined with Emtricitabine.Approved, Investigational
RibavirinRibavirin may increase the hepatotoxic activities of Emtricitabine.Approved
ValganciclovirThe risk or severity of adverse effects can be increased when Valganciclovir is combined with Emtricitabine.Approved, Investigational
Food Interactions
  • Take without regard to meals.
Synthesis ReferenceUS5538975
General References
  1. Masho SW, Wang CL, Nixon DE: Review of tenofovir-emtricitabine. Ther Clin Risk Manag. 2007 Dec;3(6):1097-104. [PubMed:18516268 ]
  2. Long MC, King JR, Acosta EP: Pharmacologic aspects of new antiretroviral drugs. Curr HIV/AIDS Rep. 2009 Feb;6(1):43-50. [PubMed:19149996 ]
  3. Authors unspecified: Emtricitabine/tenofovir disoproxil fumarate. Drugs R D. 2004;5(3):160-1. [PubMed:15139777 ]
  4. Goicoechea M, Best B: Efavirenz/emtricitabine/tenofovir disoproxil fumarate fixed-dose combination: first-line therapy for all? Expert Opin Pharmacother. 2007 Feb;8(3):371-82. [PubMed:17266471 ]
External Links
ATC CodesJ05AR03 — Tenofovir disoproxil and emtricitabineJ05AR18 — Emtricitabine, tenofovir alafenamide, elvitegravir and cobicistatJ05AR19 — Emtricitabine, tenofovir alafenamide and rilpivirineJ05AR06 — Emtricitabine, tenofovir disoproxil and efavirenzJ05AR17 — Emtricitabine and tenofovir alafenamideJ05AR09 — Emtricitabine, tenofovir disoproxil, elvitegravir and cobicistatJ05AR08 — Emtricitabine, tenofovir disoproxil and rilpivirineJ05AF09 — Emtricitabine
AHFS Codes
  • 08:18.08.20
PDB EntriesNot Available
FDA labelDownload (328 KB)
MSDSNot Available
Clinical Trials
Clinical Trials
0CompletedOtherHealthy Volunteers1
0Not Yet RecruitingOtherContraception / HIV/AIDS1
0RecruitingPreventionHuman Immunodeficiency Virus (HIV) Infections1
1CompletedNot AvailableAcquired Immune Deficiency Syndrome (AIDS)1
1CompletedNot AvailableHIV Disease2
1CompletedNot AvailableHIV-DDI1
1CompletedBasic ScienceTuberculosis1
1CompletedHealth Services ResearchHIV Disease1
1CompletedTreatmentHealthy Volunteers2
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections4
1CompletedTreatmentInsulin Resistance1
1RecruitingBasic ScienceHIV Prevention1
1RecruitingBasic ScienceHealthy Volunteers1
1RecruitingHealth Services ResearchHIV Disease1
1RecruitingPreventionHIV Disease1
1RecruitingPreventionHuman Immunodeficiency Virus (HIV) Infections1
1RecruitingTreatmentHIV Disease2
1RecruitingTreatmentInsulin Resistance1
1, 2CompletedOtherPrEP Adherence Monitoring1
1, 2CompletedTreatmentAcute HIV Infection1
1, 2CompletedTreatmentChronic Hepatitis C Infection / HIV Disease1
1, 2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections1
2Active Not RecruitingPreventionHuman Immunodeficiency Virus (HIV) Infections1
2Active Not RecruitingTreatmentContraception / HIV Disease1
2Active Not RecruitingTreatmentHIV Disease1
2Active Not RecruitingTreatmentHuman Immunodeficiency Virus (HIV) Infections1
2CompletedOtherHIV-1 Infections1
2CompletedPreventionAmphetamine-Related Disorders / HIV Disease / Human Immunodeficiency Virus (HIV) Infections1
2CompletedPreventionChronic Hepatitis B Infection1
2CompletedPreventionHIV Disease / Pregnancy1
2CompletedPreventionHIV Seroconversion / Stimulant Abuse1
2CompletedPreventionHIV Seropositivity1
2CompletedPreventionHuman Immunodeficiency Virus (HIV) Infections4
2CompletedPreventionHuman Immunodeficiency Virus (HIV) Infections / Pregnancy1
2CompletedTreatmentAcquired Immune Deficiency Syndrome (AIDS) / Human Immunodeficiency Virus (HIV) Infections2
2CompletedTreatmentAntiretroviral Naive / Human Immunodeficiency Virus (HIV) Infections1
2CompletedTreatmentChronic Hepatitis B Infection3
2CompletedTreatmentContraception / HIV Disease1
2CompletedTreatmentHIV Disease / Human Immunodeficiency Virus (HIV) Infections1
2CompletedTreatmentHIV-1 Infections6
2CompletedTreatmentHIV-1 Infections / Human Immunodeficiency Virus (HIV) Infections1
2CompletedTreatmentHepatitis B Virus (HBV) / Human Immunodeficiency Virus (HIV) Infections1
2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections11
2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Lymphoma, AIDS Related1
2CompletedTreatmentHuman Immunodeficiency Virus Type 1 (HIV-1)2
2Not Yet RecruitingPreventionHIV-1-infection1
2RecruitingTreatmentHuman Immunodeficiency Virus (HIV) Infections1
2TerminatedTreatmentHIV Disease1
2Unknown StatusPreventionHIV Transmission / Human Immunodeficiency Virus (HIV) Infections1
2Unknown StatusPreventionHuman Immunodeficiency Virus (HIV) Infections1
2Unknown StatusTreatmentHuman Immunodeficiency Virus (HIV) Infections1
2Unknown StatusTreatmentHuman Immunodeficiency Virus (HIV) Infections / Tuberculosis1
2WithdrawnTreatmentChronic Hepatitis C Infection / Human Immunodeficiency Virus (HIV) Infections1
2, 3Active Not RecruitingTreatmentAcquired Immune Deficiency Syndrome (AIDS) / Human Immunodeficiency Virus (HIV) Infections1
2, 3Active Not RecruitingTreatmentHIV Disease2
2, 3CompletedPreventionHuman Immunodeficiency Virus (HIV) Infections1
2, 3CompletedTreatmentAcute HIV Infection1
2, 3CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections2
2, 3CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Viral Hepatitis B1
2, 3RecruitingTreatmentHuman Immunodeficiency Virus Type 1 (HIV-1)1
3Active Not RecruitingTreatmentAcquired Immune Deficiency Syndrome (AIDS) / HIV Disease / Human Immunodeficiency Virus (HIV) Infections1
3Active Not RecruitingTreatmentAcquired Immune Deficiency Syndrome (AIDS) / Human Immunodeficiency Virus (HIV) Infections1
3Active Not RecruitingTreatmentHCV Infections / HIV-1 Infections1
3Active Not RecruitingTreatmentHIV Disease1
3Active Not RecruitingTreatmentHIV Disease / Human Immunodeficiency Virus (HIV) Infections4
3Active Not RecruitingTreatmentHIV-1 Infections9
3Active Not RecruitingTreatmentHIV-1 Infections / Kaposi s Sarcoma (KS)1
3Active Not RecruitingTreatmentHepatitis C, Chronic / Human Immunodeficiency Virus (HIV)1
3Active Not RecruitingTreatmentHuman Immunodeficiency Virus (HIV)1
3Active Not RecruitingTreatmentHuman Immunodeficiency Virus-type 1 Infection1
3Active Not RecruitingTreatmentPre-Exposure Prophylaxis of HIV-1 Infection1
3CompletedNot AvailableHIV Disease1
3CompletedPreventionHuman Immunodeficiency Virus (HIV) Infections3
3CompletedTreatmentAcquired Immune Deficiency Syndrome (AIDS) / Human Immunodeficiency Virus (HIV) Infections4
3CompletedTreatmentAcquired Immune Deficiency Syndrome (AIDS) / Human Immunodeficiency Virus (HIV) Infections / Human Immunodeficiency Virus Type 1 (HIV-1)1
3CompletedTreatmentAids / Human Immunodeficiency Virus (HIV) Infections1
3CompletedTreatmentChronic Hepatitis B Infection2
3CompletedTreatmentHBV / HIV Disease1
3CompletedTreatmentHIV Disease / Human Immunodeficiency Virus (HIV) Infections4
3CompletedTreatmentHIV-1 Infections5
3CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections16
3CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Tuberculosis1
3CompletedTreatmentInfection, Human Immunodeficiency Virus I1
3CompletedTreatmentViral Hepatitis B1
3Not Yet RecruitingPreventionHuman Immunodeficiency Virus (HIV) Infections1
3Not Yet RecruitingTreatmentHIV Risk1
3Not Yet RecruitingTreatmentHIV-1 Infections1
3RecruitingTreatmentHIV Disease1
3RecruitingTreatmentHIV-1 Infections2
3RecruitingTreatmentHuman Immunodeficiency Virus (HIV) Infections1
3SuspendedTreatmentHuman Immunodeficiency Virus (HIV) Infections1
3TerminatedTreatmentHIV Disease2
3TerminatedTreatmentHuman Immunodeficiency Virus Type 1 (HIV-1)1
3Unknown StatusPreventionHIV Disease / Infection NOS1
3Unknown StatusTreatmentHIV Disease1
3Unknown StatusTreatmentHuman Immunodeficiency Virus (HIV) Infections1
3WithdrawnPreventionBreastfeeding / Human Immunodeficiency Virus (HIV) Infections / Pregnancy1
4Active Not RecruitingPreventionHIV-1 Infections1
4Active Not RecruitingTreatmentChronic Infection With HIV1
4Active Not RecruitingTreatmentHIV Disease1
4Active Not RecruitingTreatmentHIV-1 Infections3
4Active Not RecruitingTreatmentHuman Immunodeficiency Virus (HIV) Infections1
4CompletedNot AvailableHIV Disease / Proteinuria1
4CompletedNot AvailableHealthy Volunteers2
4CompletedNot AvailablePharmacokinetic Study in Healthy Volunteers1
4CompletedBasic ScienceChronic Hepatitis C Infection / Human Immunodeficiency Virus (HIV) Infections1
4CompletedHealth Services ResearchHIV Disease1
4CompletedOtherAdherence to Medication Regime1
4CompletedPreventionAdolescent Behaviors / Gender / HIV Disease1
4CompletedPreventionHIV Disease3
4CompletedPreventionHIV Disease / Human Immunodeficiency Virus (HIV)1
4CompletedPreventionHIV Prevention1
4CompletedPreventionHuman Immunodeficiency Virus (HIV)1
4CompletedPreventionHuman Immunodeficiency Virus (HIV) Infections3
4CompletedTreatmentAcute HIV Infection / Human Immunodeficiency Virus (HIV) Infections1
4CompletedTreatmentAids / HIV Disease / Sleep disorders and disturbances1
4CompletedTreatmentCardiovascular Disease (CVD) / HIV Disease1
4CompletedTreatmentDyslipidemias / HIV Disease1
4CompletedTreatmentHIV Disease6
4CompletedTreatmentHIV, Combination Therapy1
4CompletedTreatmentHIV-1 Infections3
4CompletedTreatmentHealthy Volunteers1
4CompletedTreatmentHepatitis C Infection / Human Immunodeficiency Virus (HIV) Infections1
4CompletedTreatmentHuman Immunodeficiency Virus (HIV)1
4CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections17
4CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Infection, Human Immunodeficiency Virus I1
4CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Viral Hepatitis B2
4CompletedTreatmentHuman Immunodeficiency Virus Type 1 (HIV-1)4
4Enrolling by InvitationPreventionHIV/AIDS1
4Enrolling by InvitationTreatmentHIV Disease1
4Not Yet RecruitingTreatmentBone destruction / HIV Disease / Menopause1
4Not Yet RecruitingTreatmentHepatitis B,Chronic1
4Not Yet RecruitingTreatmentHepatitis B,Chronic / Pregnancy1
4RecruitingPreventionBone Demineralization1
4RecruitingPreventionHIV Disease1
4RecruitingPreventionHIV Disease / STI1
4RecruitingPreventionPrEP Adherence Monitoring1
4RecruitingSupportive CareHIV Disease1
4RecruitingTreatmentAntiretroviral Therapy Intolerance / Patients Compliance1
4RecruitingTreatmentHIV Associated Neurocognitive Disorders (HAND) / Neurocognitive Decline1
4RecruitingTreatmentHIV Disease1
4RecruitingTreatmentHIV Disease / Renal Insufficiency,Chronic / Therapeutic Agent Toxicity1
4RecruitingTreatmentHuman Immunodeficiency Virus (HIV) Infections / Osteopenia1
4TerminatedPreventionHIV Disease1
4TerminatedTreatmentAcquired Immune Deficiency Syndrome (AIDS)1
4TerminatedTreatmentHIV Disease2
4TerminatedTreatmentHIV Disease / Human Immunodeficiency Virus (HIV) Infections1
4Unknown StatusBasic ScienceHIV Disease1
4Unknown StatusPreventionHIV Disease1
4Unknown StatusPreventionHepatitis B,Chronic / Pregnancy1
4Unknown StatusTreatmentHIV Disease1
4Unknown StatusTreatmentHepatitis B,Chronic1
4Unknown StatusTreatmentHuman Immunodeficiency Virus (HIV) Infections2
4WithdrawnTreatmentAcquired Immune Deficiency Syndrome (AIDS) / Human Immunodeficiency Virus (HIV) Infections1
4WithdrawnTreatmentViral Hepatitis B1
Not AvailableActive Not RecruitingPreventionHIV Disease1
Not AvailableCompletedNot AvailableHIV Disease1
Not AvailableCompletedNot AvailableHIV-1 Infections1
Not AvailableCompletedNot AvailableHuman Immunodeficiency Virus (HIV)1
Not AvailableCompletedNot AvailableHuman Immunodeficiency Virus (HIV) Infections4
Not AvailableCompletedBasic ScienceHIV Disease1
Not AvailableCompletedPreventionHIV Disease2
Not AvailableCompletedPreventionHuman Immunodeficiency Virus (HIV) Infections4
Not AvailableCompletedTreatmentHIV Disease1
Not AvailableCompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections2
Not AvailableCompletedTreatmentPrimary Biliary Cirrhosis (PBC)1
Not AvailableEnrolling by InvitationPreventionHIV Disease1
Not AvailableNot Yet RecruitingBasic ScienceHealthy Volunteers / Pharmacokinetics1
Not AvailableNot Yet RecruitingPreventionHIV-1 Infections1
Not AvailableRecruitingNot AvailableHIV Chemoprophylaxis / HIV Preexposure Prophylaxis1
Not AvailableRecruitingNot AvailableHIV Disease / Illicit Drug User1
Not AvailableRecruitingNot AvailableHIV Prevention1
Not AvailableRecruitingNot AvailableHIV Seropositivity / Pregnancy, High-Risk1
Not AvailableRecruitingNot AvailableHIV/AIDS / Inflammation Vagina / Menopause1
Not AvailableRecruitingNot AvailableHuman Immunodeficiency Virus (HIV)1
Not AvailableRecruitingNot AvailableHuman Immunodeficiency Virus (HIV) Infections1
Not AvailableRecruitingBasic ScienceHIV Disease2
Not AvailableRecruitingPreventionHIV Disease3
Not AvailableRecruitingPreventionHIV/AIDS1
Not AvailableRecruitingPreventionHuman Immunodeficiency Virus (HIV)1
Not AvailableRecruitingTreatmentHIV Disease / Infertilities1
Not AvailableRecruitingTreatmentHuman Immunodeficiency Virus (HIV) Infections1
Not AvailableTerminatedTreatmentAids / HIV Disease / Tuberculosis1
Not AvailableUnknown StatusBasic ScienceHuman Immunodeficiency Virus (HIV) Infections1
Not AvailableUnknown StatusPreventionHIV Disease / Human Immunodeficiency Virus (HIV) Infections / Immune Reconstitution Inflammatory Syndrome1
Not AvailableWithdrawnNot AvailableHIV Disease1
Not AvailableWithdrawnNot AvailableHIV Infected1
Not AvailableWithdrawnBasic ScienceHuman Immunodeficiency Virus (HIV) Infections1
Not AvailableWithdrawnTreatmentHuman Immunodeficiency Virus (HIV) Infections1
  • Gilead sciences inc
Dosage forms
Tablet, film coatedOral
CapsuleOral200 mg/1
CapsuleOral200 mg
SolutionOral10 mg/mL
Unit descriptionCostUnit
Emtriva 200 mg capsule21.75USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2075189 No2004-11-302011-01-31Canada
US5814639 Yes1996-03-292016-03-29Us
US5914331 Yes1998-01-022018-01-02Us
US5922695 Yes1998-01-252018-01-25Us
US5935946 Yes1998-01-252018-01-25Us
US5977089 Yes1998-01-252018-01-25Us
US6043230 Yes1998-01-252018-01-25Us
US6639071 Yes1998-08-142018-08-14Us
US6642245 Yes2001-05-042021-05-04Us
US6703396 Yes2001-09-092021-09-09Us
US6838464 No2001-02-262021-02-26Us
US6939964 Yes1998-07-202018-07-20Us
US7067522 No1999-12-202019-12-20Us
US7125879 No2002-08-092022-08-09Us
US7176220 No2003-11-202023-11-20Us
US7390791 No2002-05-072022-05-07Us
US7402588 No1993-02-012010-02-01Us
US7635704 No2006-10-262026-10-26Us
US7800788 No2002-02-022022-02-02Us
US7803788 No2002-02-022022-02-02Us
US8080551 No2003-04-112023-04-11Us
US8101629 No2002-08-092022-08-09Us
US8148374 No2009-09-032029-09-03Us
US8592397 No2004-01-132024-01-13Us
US8598185 No2008-05-012028-05-01Us
US8633219 No2010-04-242030-04-24Us
US8716264 No2004-01-132024-01-13Us
US8754065 No2012-08-152032-08-15Us
US8841310 No2005-12-092025-12-09Us
US8981103 No2006-10-262026-10-26Us
US9018192 No2006-06-132026-06-13Us
US9296769 No2012-08-152032-08-15Us
Experimental Properties
melting point (°C)136-140 °CNot Available
water solubility112 mg/mLNot Available
logP-1.4Not Available
pKa2.65Not Available
Predicted Properties
Water Solubility2.0 mg/mLALOGPS
pKa (Strongest Acidic)14.29ChemAxon
pKa (Strongest Basic)-3.1ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area88.15 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity55.37 m3·mol-1ChemAxon
Polarizability21.79 Å3ChemAxon
Number of Rings2ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Human Intestinal Absorption+0.9944
Blood Brain Barrier+0.9742
Caco-2 permeable-0.7053
P-glycoprotein substrateNon-substrate0.7363
P-glycoprotein inhibitor INon-inhibitor0.933
P-glycoprotein inhibitor IINon-inhibitor0.9806
Renal organic cation transporterNon-inhibitor0.8614
CYP450 2C9 substrateNon-substrate0.7945
CYP450 2D6 substrateNon-substrate0.8401
CYP450 3A4 substrateNon-substrate0.625
CYP450 1A2 substrateNon-inhibitor0.7748
CYP450 2C9 inhibitorNon-inhibitor0.7384
CYP450 2D6 inhibitorNon-inhibitor0.8666
CYP450 2C19 inhibitorNon-inhibitor0.7947
CYP450 3A4 inhibitorNon-inhibitor0.6915
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7653
Ames testAMES toxic0.5304
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.4133 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9861
hERG inhibition (predictor II)Non-inhibitor0.7827
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Mass Spec (NIST)Not Available
Spectrum TypeDescriptionSplash Key
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QFT , negativesplash10-0udi-0900000000-70cf3fd58a0517da4a55View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QFT , negativesplash10-0udi-0900000000-94b3e0720e27e6745a1fView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QFT , negativesplash10-0udi-0900000000-8dbfc14b46cc1f58e910View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QFT , negativesplash10-0udi-0900000000-2dad282fe8707980881dView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QFT , negativesplash10-0udi-1900000000-efef9ecafd739446f7aeView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QFT , negativesplash10-0udi-2900000000-349c2005cbcd9008b160View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QFT , positivesplash10-001i-0900000000-6dae6d5531a8a2f408cdView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QFT , positivesplash10-001i-0900000000-b8b0b2a41b04924a3ae6View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QFT , positivesplash10-001i-0900000000-b0b20b1959137a52d9c7View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QFT , positivesplash10-001i-0900000000-bd2c9f863694963a9078View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QFT , positivesplash10-001i-1900000000-9903921aee7742b373e7View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QFT , positivesplash10-001i-1900000000-8857a02a53df79efbd5cView in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
DescriptionThis compound belongs to the class of organic compounds known as 3'-thia pyrimidine nucleosides. These are nucleoside analogues with a structure that consists of a pyrimidine base, which is N-substituted at the 1-position with a 3'-thia derivative (1,3-oxazolidine) of the ribose moiety that is characteristic of nucleosides.
KingdomOrganic compounds
Super ClassNucleosides, nucleotides, and analogues
ClassNucleoside and nucleotide analogues
Sub Class3'-thia pyrimidine nucleosides
Direct Parent3'-thia pyrimidine nucleosides
Alternative ParentsPyrimidones / Aminopyrimidines and derivatives / Halopyrimidines / Aryl fluorides / Hydropyrimidines / Imidolactams / Oxathiolanes / Heteroaromatic compounds / Monothioacetals / Oxacyclic compounds
Substituents3'-thia pyrimidine nucleoside / Aminopyrimidine / Halopyrimidine / Pyrimidone / Aryl fluoride / Aryl halide / Hydropyrimidine / Pyrimidine / Imidolactam / Heteroaromatic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptorsorganofluorine compound, pyrimidone, nucleoside analogue, monothioacetal (CHEBI:31536 )


Human immunodeficiency virus 1
Pharmacological action
General Function:
Rna-dna hybrid ribonuclease activity
Specific Function:
Not Available
Gene Name:
Uniprot ID:
Uniprot Name:
Reverse transcriptase/RNaseH
Molecular Weight:
65223.615 Da
  1. Modrzejewski KA, Herman RA: Emtricitabine: a once-daily nucleoside reverse transcriptase inhibitor. Ann Pharmacother. 2004 Jun;38(6):1006-14. Epub 2004 Apr 30. [PubMed:15121999 ]
  2. Bang LM, Scott LJ: Emtricitabine: an antiretroviral agent for HIV infection. Drugs. 2003;63(22):2413-24; discussion 2425-6. [PubMed:14609348 ]
  3. Molina JM, Cox SL: Emtricitabine: a novel nucleoside reverse transcriptase inhibitor. Drugs Today (Barc). 2005 Apr;41(4):241-52. [PubMed:16034488 ]


Pharmacological action
General Function:
Protein homodimerization activity
Specific Function:
Required for the phosphorylation of the deoxyribonucleosides deoxycytidine (dC), deoxyguanosine (dG) and deoxyadenosine (dA). Has broad substrate specificity, and does not display selectivity based on the chirality of the substrate. It is also an essential enzyme for the phosphorylation of numerous nucleoside analogs widely employed as antiviral and chemotherapeutic agents.
Gene Name:
Uniprot ID:
Uniprot Name:
Deoxycytidine kinase
Molecular Weight:
30518.315 Da
  1. Bethell R, De Muys J, Lippens J, Richard A, Hamelin B, Ren C, Collins P: In vitro interactions between apricitabine and other deoxycytidine analogues. Antimicrob Agents Chemother. 2007 Aug;51(8):2948-53. Epub 2007 May 21. [PubMed:17517847 ]


Pharmacological action
General Function:
Toxic substance binding
Specific Function:
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc.
Gene Name:
Uniprot ID:
Uniprot Name:
Serum albumin
Molecular Weight:
69365.94 Da
  1. Bocedi A, Notaril S, Narciso P, Bolli A, Fasano M, Ascenzi P: Binding of anti-HIV drugs to human serum albumin. IUBMB Life. 2004 Oct;56(10):609-14. [PubMed:15814459 ]
  2. Bocedi A, Notari S, Menegatti E, Fanali G, Fasano M, Ascenzi P: Allosteric modulation of anti-HIV drug and ferric heme binding to human serum albumin. FEBS J. 2005 Dec;272(24):6287-96. [PubMed:16336266 ]
Drug created on June 13, 2005 07:24 / Updated on July 25, 2017 17:53